NO20020151L - Veksthormonformuleringer - Google Patents

Veksthormonformuleringer

Info

Publication number
NO20020151L
NO20020151L NO20020151A NO20020151A NO20020151L NO 20020151 L NO20020151 L NO 20020151L NO 20020151 A NO20020151 A NO 20020151A NO 20020151 A NO20020151 A NO 20020151A NO 20020151 L NO20020151 L NO 20020151L
Authority
NO
Norway
Prior art keywords
growth hormone
result
temperatures
formulation
mannitol
Prior art date
Application number
NO20020151A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020151D0 (no
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020151(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of NO20020151D0 publication Critical patent/NO20020151D0/no
Publication of NO20020151L publication Critical patent/NO20020151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
NO20020151A 1999-07-12 2002-01-11 Veksthormonformuleringer NO20020151L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (2)

Publication Number Publication Date
NO20020151D0 NO20020151D0 (no) 2002-01-11
NO20020151L true NO20020151L (no) 2002-03-12

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020151A NO20020151L (no) 1999-07-12 2002-01-11 Veksthormonformuleringer

Country Status (25)

Country Link
US (1) US20060029635A1 (enExample)
EP (1) EP1194170B1 (enExample)
JP (3) JP2003504346A (enExample)
KR (1) KR20020031388A (enExample)
CN (1) CN1360506A (enExample)
AR (1) AR024728A1 (enExample)
AT (1) ATE386501T1 (enExample)
AU (1) AU775107C (enExample)
BR (1) BR0013162A (enExample)
CA (1) CA2378949C (enExample)
CZ (1) CZ200260A3 (enExample)
DE (1) DE60038118T2 (enExample)
ES (1) ES2300268T3 (enExample)
HK (1) HK1046358A1 (enExample)
HU (1) HUP0202189A3 (enExample)
IL (2) IL147253A0 (enExample)
MX (1) MXPA02000404A (enExample)
NO (1) NO20020151L (enExample)
NZ (1) NZ516507A (enExample)
PL (1) PL353238A1 (enExample)
SI (1) SI1194170T1 (enExample)
SK (1) SK252002A3 (enExample)
TR (1) TR200200034T2 (enExample)
TW (1) TWI247608B (enExample)
WO (1) WO2001003741A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
AU2003249992A1 (en) * 2002-07-09 2004-01-23 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
JP2007506683A (ja) * 2003-09-25 2007-03-22 カンジェーン コーポレイション ヒト成長ホルモン剤およびその調整方法と使用方法
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
US20140194356A1 (en) 2011-07-25 2014-07-10 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
JP6179690B1 (ja) 2015-12-10 2017-08-16 三菱瓦斯化学株式会社 光硬化性組成物及び光学材料
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
AU2021379990A1 (en) * 2020-11-16 2023-06-29 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
BR8603586A (pt) * 1985-07-30 1987-03-10 Int Minerals & Chem Corp Processo para manter a fluidez de um homonio;processo para efetuar a promocao de crescimento em animais e formulacao promotora de crescimento
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DE69110290T2 (de) * 1990-09-21 1995-10-19 Novonordisk As Adaptor.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
DE69709069T2 (de) * 1996-02-13 2002-07-04 G.D. Searle & Co., Chicago Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
BR0013162A (pt) 2002-05-28
SK252002A3 (en) 2002-06-04
CN1360506A (zh) 2002-07-24
CA2378949A1 (en) 2001-01-18
KR20020031388A (ko) 2002-05-01
IL147253A (en) 2007-07-24
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27
CZ200260A3 (cs) 2002-04-17
HUP0202189A2 (en) 2002-10-28
DE60038118D1 (de) 2008-04-03
CA2378949C (en) 2015-03-31
AU775107B2 (en) 2004-07-15
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15
AU775107C (en) 2005-02-24
TWI247608B (en) 2006-01-21
TR200200034T2 (tr) 2002-05-21
JP2003504346A (ja) 2003-02-04
JP5941496B2 (ja) 2016-06-29
ATE386501T1 (de) 2008-03-15
JP2014208656A (ja) 2014-11-06
WO2001003741B1 (en) 2001-04-19
SI1194170T1 (sl) 2008-10-31
DE60038118T2 (de) 2009-03-05
EP1194170A1 (en) 2002-04-10
HK1046358A1 (zh) 2003-01-10
AU5997500A (en) 2001-01-30
ES2300268T3 (es) 2008-06-16
WO2001003741A1 (en) 2001-01-18
HUP0202189A3 (en) 2003-07-28
NO20020151D0 (no) 2002-01-11
AR024728A1 (es) 2002-10-23
EP1194170B1 (en) 2008-02-20
US20060029635A1 (en) 2006-02-09
PL353238A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
MXPA02000404A (es) Formulaciones de hormona de crecimiento.
CN108107210A (zh) 一种髓过氧化物酶冻干校准品的制备方法及冻干保护液
US4226940A (en) Non-frozen concentrated bacterial cultures
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
DE60221621D1 (de) Lagerstabiles Nahrungsmittelprodukt enthaltend Molkenprotein, Verfahren zu seiner Herstellung und Verwendung
US20150329605A1 (en) Method for stabilizing protein
CN114752703A (zh) 一种新型冠状病毒核酸的冻干型检测试剂及其制备方法
CN108315261A (zh) 一种食用菌保藏培养基及其制备方法
CN105733947A (zh) 一种茶树菇菌种低温保藏及解冻方法
CN113229288A (zh) 一种新型低温冷链季铵盐消毒剂及其制备方法
US20030186212A1 (en) Semen extender composition and methods for manufacturing and using
CN101642572A (zh) 海洋微生物溶菌酶保护冻干粉的制造方法
BRPI0509321B1 (pt) Processos de preparação na panificação de um melhorador líquido e de uma massa para produto cozido de panificação, melhorador e uso de um melhorador
CN101019570B (zh) 哈密瓜专用保鲜剂
CN111789100B (zh) 一种无dmso的冷冻保存液在卵母细胞或胚胎冷冻保存中的应用
CN105925483A (zh) 一种真姬菇菌种低温保藏及解冻方法
WO2023072137A1 (zh) 蛋白稳定剂、试剂盒和保护蛋白的方法
Bray The chemistry of xanthine oxidase. 6. Variations in stability and the presence of an inhibitor in certain preparations
US6579707B2 (en) Stabilization of enzymes during freezing
CN110065688A (zh) 一种猪粪源生物肥料的生产包装方法
CN108077244A (zh) 一种长效猪精液稀释粉
KR102123805B1 (ko) 클로렐라의 냉동 보관 방법
CN108498467A (zh) 注射用重组人生长激素无菌粉末及其制备方法
CN101775380B (zh) 甜菜碱作为丙氨酸氨基转移酶稳定剂的应用及丙氨酸氨基转移酶校准品组合物
Williamson Selective media in the enumeration of bacteria in pitching yeasts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application